Cerevel Therapeutics Holdings, Inc.

Equities

CERE

US15678U1280

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
42.47 ^USD	+0.95%		+0.62%	+0.17%

Apr. 18	Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	MT
Apr. 18	Cerevel Therapeutics' Potential Parkinson's Treatment Meets Primary Endpoint in Phase 3 Study	MT

Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

February 27, 2024 at 04:02 pm EST

Cerevel Therapeutics Holdings, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 432.84 million compared to USD 351.51 million a year ago. Basic loss per share from continuing operations was USD 2.67 compared to USD 2.32 a year ago.

Latest news about Cerevel Therapeutics Holdings, Inc.

Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	Apr. 18	MT
Cerevel Therapeutics' Potential Parkinson's Treatment Meets Primary Endpoint in Phase 3 Study	Apr. 18	MT
Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study	Apr. 18	RE
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson?s Disease	Apr. 18	CI
Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation	Mar. 25	MT
Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,057,890, According to a Recent SEC Filing	Mar. 04	MT
Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Sector Update: Health Care Stocks Gain Late Afternoon	Feb. 22	MT
AbbVie Plans $13 Billion Bond Sale to Fund Acquisitions	Feb. 22	MT
Phew! The party continues!	Feb. 22
AbbVie eyes selling at least $13 bln of bonds to fund M&A, Bloomberg reports	Feb. 21	RE
North American Morning Briefing : Stock Futures -2-	Feb. 21	DJ
AbbVie CEO to Retire; COO Robert Michael Named Successor	Feb. 20	MT
Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating	Feb. 15	MT
BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase	Feb. 13	AN
AbbVie Completes $10.1 Billion Acquisition of ImmunoGen, Lowers Q1 Adjusted EPS Guidance	Feb. 12	MT
AbbVie 4Q Sales Lower as Himura Revenue Sinks	Feb. 02	DJ
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals	Feb. 02	RE
Neumora Therapeutics Names Kaya Pai Panandiker as Chief Commercial Officer	Jan. 22	MT
Cerevel Therapeutics Holdings Insider Sold Shares Worth $424,700, According to a Recent SEC Filing	Dec. 28	MT
JPMorgan Raises Price Target on Cerevel Therapeutics Holdings to $45 From $25, Keeps Neutral Rating	Dec. 28	MT
Cerevel Therapeutics Holdings Insider Sold Shares Worth $331,608, According to a Recent SEC Filing	Dec. 27	MT
Jefferies Downgrades Cerevel Therapeutics to Hold From Buy, Adjusts Price Target to $45 From $40	Dec. 22	MT
Cerevel Therapeutics Holdings Insider Sold Shares Worth $571,972, According to a Recent SEC Filing	Dec. 22	MT
Cerevel Therapeutics Holdings Insider Sold Shares Worth $259,144, According to a Recent SEC Filing	Dec. 22	MT

Chart Cerevel Therapeutics Holdings, Inc.

Duration

Period

Chart Cerevel Therapeutics Holdings, Inc.

More charts

Company Profile

Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimerâs disease psychosis, epilepsy, panic disorder and Parkinsonâs disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinsonâs disease.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

42.47 USD

Average target price

44.78 USD

Spread / Average Target

+5.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CEREVEL THERAPEUTICS HOLDINGS, INC.	+0.17%	7.71B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs